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Abstract
Genetically encoded FRET glucose nanosensors have proven to be useful for imaging glucose flux in HepG2 cells. However, the dynamic range
of the original sensor was limited and thus it did not appear optimal for high throughput screening of siRNA populations for identifying proteins
involved in regulation of sugar flux. Here we describe a hybrid approach that combines linker-shortening with fluorophore-insertion to decrease the
degrees of freedom for fluorophore positioning leading to improved nanosensor dynamics. We were able to develop a novel highly sensitive FRET
nanosensor that shows a 10-fold higher ratio change and dynamic range (0.05–11 mM) in vivo, permitting analyses in the physiologically relevant
range. As a proof of concept that this sensor can be used to screen for proteins playing a role in sugar flux and its control, we used siRNA inhibition of
GLUT family members and show that GLUT1 is the major glucose transporter in HepG2 cells and that GLUT9 contributes as well, however to a
lower extent. GFP fusions suggest that GLUT1 and 9 are preferentially localized to the plasma membrane and thus can account for the transport
activity. The improved sensitivity of the novel glucose nanosensor increases the reliability of in vivo glucose flux analyses, and provides a newmeans
for the screening of siRNA collections as well as drugs using high-content screens.
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Glucose levels are maintained within tight limits to ascertain
sufficient energy supply to the brain and other peripheral organs
and to prevent accumulation to toxic concentrations. Homeostasis
is achieved by the hormones insulin and glucagon, affecting
glucose uptake, release and metabolism in glucose-responsive
tissues. The response of mammalian cells to fluctuations in
glucose levels is of major relevance, since alterations are important
for pathological conditions, i.e. obesity or type-2 diabetes. It is well
established that yeast and other organisms use a complex set of
signaling networks to control sugar flux, e.g. to acclimate uptake to
availability and needs of the cell, however little is still known aboutAbbreviations: FLIP, fluorescent indicator protein; FLIIP, fluorescent
intramolecular indicator protein; FRET, fluorescence resonance energy transfer;
Gluc, glucose; CYT, cytosol
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doi:10.1016/j.bbamem.2007.11.015the mechanisms that control glucose flux in glucose-responsive
tissues in human cells [1]. Similar as in yeast, the human genome
encodes more than 10 glucose uniporters (GLUTs) for uptake and
release and several hexokinases for metabolism. Given that sugars
serve as signaling molecules in many organisms, it is conceivable
that besides the insulin/glucagon system glucose and its
metabolisms also influence other mechanisms to control sugar
flux. The recent availability of large siRNA collections in com-
bination with imaging based screening systems has enabled
genome-wide screens for signaling components [2]. Similar
screens could be performed if suitable high throughput detection
systems would be available for glucose.
To monitor the glucose flux in living cells, a FRET glucose-
imaging platform has recently been developed consisting of a set
of sensors with different affinities for glucose. These glucose
nanosensors exploit resonance energy transfer between a
coupled pair of cyan and yellow fluorescent proteins (eCFP,
eYFP) to detect conformational changes induced by sugar-
binding [3,4]. The glucose-binding domain was derived from
chemotactic receptors of bacteria, namely the glucose/galactose-
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energy transfer was observed upon glucose binding for the first
generation of FRET sensors [5]. While this sensor was used
successfully to monitor glucose flux in the cytosol, nucleus and
ER of COS-7 or HepG2 cells, both the range of FLIPglu-600µ
(Fig. 1) as well as the signal-to-noise ratio (SNR) appear
too limited and would thus reduce the discovery rate in high
throughput screens for signaling components via siRNA [5].
As a first step to make the sensors more robust, the pH and
chloride-sensitive eYFP was replaced by citrine [6]. Glucose
sensors with improved SNR and a larger dynamic range had been
developed by two approaches, namely linker deletions and by
insertion of the fluorophore into the backbone of MglB with the
rationale of decreasing the degrees of freedom of rotation of the
fluorophores [7]. The artificial linker and less well-structured
domains at the termini of MglB and eCFP and MglB and Citrine-
eYFP variants (together comprising the “composite linker”) pre-
sumably allow flexible rotation of Citrine-eYFP and thus affect
the probability of obtaining a productive resonance energy transfer
[7]. Deletion of these domains lead to FLIPglu-600µΔ13 which
showed an over four times higher ratio change compared to the
original sensor. The insertional sensor FLII12Pglu-600µ showed
a N10 times higher ratio change over the original FLIPglu-600µ as
determined in vitro. Here, the two strategies were combined to
improve in vivo SNR and thus the detection range.
The improved FRET sensors, which cover the physiological
blood glucose range, qPCR, eGFP fusion as well as an imaging-
based screen a GLUT siRNA collection, were used to determine
the contribution of GLUT glucose uniporters to glucose uptake in
HepG2 cells. The results demonstrate the feasibility of highFig. 1. In vivo detection range of FLIP nanosensors. The detection range of
FLII12Pglu-700µ δ 6 (pink) and FLIPglu-600µ (blue) was determined using in vivo
FRETmeasurements (shown in Fig. 3). The (Ctrine-eYFP)/eCFP emission ratiowas
normalized to the starting ratio. Base-line noisewas ~0.1. The reliable concentration
ranges of FLII12Pglu-700µδ6 and FLIPglu-600µ were 0.074 to 6.1 mM and 0.05 to
9.6 mM, respectively. The in vivo glucose concentration was calculated using the
equation [gluc]cyt=K0.5×(r−1)/(Rmax− r). Rmax is the maximum ratio change; r is
the ratio. The K0.5 was assumed to be identical as under in vitro conditions.throughput RNAi screens using the novel FRET sensors and
shows that GLUT1 and GLUT9 are the major contributors to
glucose uptake in HepG2 cells.
2. Materials and methods
2.1. Plasmid constructs
For in vitro protein assays, all FLII12Pglu-600µ series nanosensors were cloned
in pRSET-B (Invitrogen). For mammalian cell imaging assays, FLII12Pglu-600µ
FLII12Pglu-10aa, FLII12Pglu-15aa, FLII12D183A, FLII12Pglu-δ4 and FLII12Pglu-δ6
were transferred into pcDNA3.1(−) (Invitrogen) using BamHI and HindIII. To
analyze the localization of GLUT1 and GLUT9, GLUT1-eGFP and GLUT9-eGFP
were cloned into pENTR/D-TOPO (Invitrogen) using GLUT1-forward primer
(CACCGGAGCCCAGCAGCAAGAAGCTG) and GLUT1-reverse primer
(CACTTGGGAATCAGCCCCCAGGGGAT), GLUT9-forward primer (CACCT-
CACTGAGACCCATGGCAAGGAAACAAAA) and GLUT9-reverse primer
(AGGCCTTCCATTTATCTTACCATCAGTG). An EcoRV site was inserted at
the 3′-end of eGFP in pCMS-eGFP (Clontech) and mCherry [8] was cloned in
BamHI and EcoRV sites in the modified pCMS-eGFP thereby removing eGFP
(pCMS-mCherry). A Gateway cassette (restricted with KpnI, blunt-end treated with
theKlenowpolymerase fragment and subsequently restrictedwith SpeI)was inserted
in themultiple cloning site of pCMS-mCherry (restrictedwithNotI, blunt-end treated
with the Klenow polymerase fragment with dNTPs and subsequently restricted with
NheI) resulting in pCMSmCherry-GATEWAY. The GLUT-eGFP fusions were
subcloned into pCMSmCherry-GATEWAY using the Gateway BP reaction
(Invitrogen).
2.2. Linker deletions for FLIPglu internally fused nanosensors
The linker and less well-structured domains between the termini of MglB and
Citrine-eYFP (together comprising the 17 amino acid “composite linker”) were
systematically deleted from the internally fused glucose nanosensor FLII12Pglu-
600µ [7] using Kunkel mutagenesis [9]. Seventeen primers were used to delete
amino acid residues starting from the C-terminus of MglB from FLII12Pglu-600µ
creating FLII12Pglu-1aa through FLII12Pglu-17aa and to delete 4 and 6 amino acid
residues Gly-Ala-Gly-Thr-Gly-Gly (ggcgccggtaccggtgga) of the plasmid derived
linker between the MglB and Citrine-eYFP keeping the MglB and Citrine-eYFP
intact (FLII12Pglu-δ4 and FLII12Pglu-δ6) (Fig. 2).
2.3. In vitro analysis of nanosensors
Constructs were transferred to E. coli BL21(DE3) Gold (Stratagene, USA)
using electroporation, protein was extracted and purified as previously described
[5]. Emission spectra and ligand titration curves were obtained using a
monochromator microplate reader (Safire, Tecan, Austria; excitation 433/12 nm;
emission of eCFP: 485/12 nm; Citrine-eYFP: 528/12). Titrations were carried out
in 20 mM MOPS pH 7. To compare the FLII12Pglu-600µ series, Citrine-eYFP
emission intensity values for each protein was set to ~20,000 RFU (emission gain
80). The nanosensors were also analyzed in Hanks' balanced buffer (137 mM
NaCl, 5.4 mM KCl, 0.3 mM Na2HPO4, 0.4 mM KH2PO4, 4.2 mM NaHCO3,
1.3 mM CaCl2, 0.5 mMMgCl2, 0.6 mMMgSO4, pH 7.4) or artificial mammalian
cytosol (135 mM K-gluconate, 4 mM KCl, 12 mM NaHCO3, 0.8 mM MgCl2,
0.2 mMCaCl2; pH 7.2). The Kd of each nanosensor was determined by fitting to a
single site binding isotherm: S=(r− rapo)/(rsat− rapo)=[gluc]/ (Kd+[gluc]), where S
is saturated-binding portion; [gluc], glucose concentration; r, ratio; rapo, ratio in the
absence of glucose; and rsat, ratio at saturation with ligand. Normalized ratio
changes were calculated from the function: rnorm=r / rapo. Measurements were
performed with at least three independent protein extracts. eCFP emission is
characterized by two peaks at 485 and 502 nm; the ratio was defined here as the
fluorescence intensity at 528 nm divided by the intensity at 485 nm.
2.4. Cell culture and transfection
HepG2 cells were grown in DMEM with 10% fetal calf serum and 50 U/ml
penicillin and 50 μg/ml streptomycin (Invitrogen). Cells were cultured at 37 °C
and 5% CO2. For siRNA analysis, stable cell lines expressing the nanosensor
Fig. 2. FLII12Pglu series nanosensor with enhanced in vitro signal change. (A) FLII12Pglu construct consisting of N-terminal His-tag, N-terminal 12 amino acids of
MglB (pink), eCFP (cyan), 13–304 amino acid of MglB (pink), a C-terminal composite linker, and Citrine-eYFP (yellow). (B) Top graph: Effect of number of amino
acid deletion on Δratio change in 20 mM MOPS buffer. The Δratio of each nanosensor was determined by titration with glucose (0–100 mM). Closed circles show
deletion constructs, open circle shows synthetic linker-deletion constructs, the open triangle shows the original nanosensor FLII12Pglu-600µ. Bottom graph: Effect of the
number of amino acids deleted onΔratio change in Hanks' balanced buffer (pH 7.4). (C) Correlation ofΔratio change between in Hanks' balanced buffer and artificial
cytosol. Data were fitted by linear regression.
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by selection on 400 µg/ml geneticin for two weeks. For perfusion-imaging
analysis, the transient FRET-sensor-transformed cells were cultured on round
cover glasses (2.5 mm diameter) in 6-well plates. On the second day after
transformation, the cover glasses with the cells were mounted in a perfusion-
chamber (Vacu-Cell™ perfusion chambers, Mini Configuration, Thin Window
Model VC-MPC-TW (C&L Instruments, Inc). For ImageXpress analysis, the
stable FRET-sensor-transformed cells were grown on 96 well plates, siRNA
from the ATP carbohydrate transporter siRNA library (Ambion) was transfected
using siPORT™ NeoFX™ (Ambion) at final siRNA concentrations of 30 nm at
cell density of 8000 cells/well. The siRNA concentration and cell density for the
transfection was optimized with the help of the KDalert GAPDH Assay Kit
(Ambion), allowing measurement of GAPDH enzymatic activity in siRNA
treated cell lysates at excitation wavelength 560 nm and emission wavelength
590 nm in the fluorimeter. Cy3-negative control oligonucleotides (Ambion)
were co-transformed to identify transfected cells.
2.5. FRET image analysis
Imaging was performed on an inverted fluorescence microscope (Leica
DMIRE2; http://www.leica.com) with a Quant EM digital camera (Photo-
metrics; http://www.photomet.com) and 40×/NA1.25–0.75-oil immersion lens
(IMM HCxPL Apo CS). Dual emission intensity ratios were simultaneously
recorded using a DualView unit with a Dual CFP/YFP-ET filter set (ET470/
24m, ET535/30m Chroma) and Metafluor 6.1r1 software (Universal Imaging).
Excitation (filter ET430/24x Chroma) was provided by a Lambda DG4 light
source (Sutter Instruments; http://www.sutter.com; 100% lamp output). A high
end imaging system as described here is not necessary for recording of the FRET
data described here, e.g. the galvanometric mirror of the DG4 was not used forexcitation, and Sensys or Coolsnap HQ cameras had previously been used to
obtain high quality data with less sensitive nanosensors. Simpler systems (as
described in Fehr et al., [5,10] ) with more basic instrumentation such as mercury
lamps typically used for and less sensitive cameras are sufficient for most
applications. Images were acquired within the linear detection range of the
camera at intervals of 5–10 s. Depending on expression level of different
nanosensors, exposure time was typically 1000 ms with an EM gain of 3× at
10 MHz. Perfusion was performed with Hanks' balanced buffer at 1.0 ml/min in
a vacuum chamber (Vacu-Cell VC-MPC-TW, C&L Instruments; http://www.
fluorescence.com/) with a total volume of 50 µM using the ValveBank II
perfusion system (AutoMate Scientific; http://www.autom8.com). The baselines
throughout the experiment were corrected using a 3rd order polynomial fit of the
ratios measured in the absence of glucose. Each experiment was measured in
more than triplicate and a representative result is shown.
2.6. In vivo apparent K0.5
The in vivo apparent K0.5 of each nanosensor was determined by fitting to the
Michaelis–Menten equation; r=[gluc]×Rmax/(K0.5+[gluc]); [gluc] is the extra-
cellular glucose concentration; r is the initial ratio change rate after glucose loading
(Δratio/sec). To determine the initial flux rate in vivo, the initial accumulation ratewas
calculated from the time-dependent ratio plots during 2–10 s after glucose loading.
2.7. siRNA screen on the ImageXpress
To analyze the effect of siRNA on glucose concentration change in HepG2
cells, ratio imaging was performed using an ImageXpress5000A (Molecular
Devices). The eCFP, Citrine and Cy3 images were acquired by filter switching
with ex-filter D436-20x/em-filter HQ480-40 m/dichroic filter Q455D CLP, ex-
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HQ560-50x/em-filter HQ645-75 m/dichroic filter Q595LP, respectively with an
exposure time of 100 ms at 15 s intervals. Glucose (50 µL) was added at 1 and
2.5 min, to the desired final concentration (starting buffer volume was 100 µL).
Cellular image analysis was performed using MetaXpress. Statistical signifi-
cance was analyzed using the t-test for independent samples.
2.8. Confocal microscopy
FLII12Pglu700µ-δ6, GLUT1-eGFP, GLUT9-eGFP, were transiently
expressed in HepG2 cells and cells were imaged 24–48 h after transfection by
using a Nipkow spinning disk confocal microscope. Incident argon (488 nm) and
krypton (458 nm) ion laser (Coherent, Inc.) beams were coupled to a modified
Yokogawa spinning disk confocal scan head (Yokogawa Electric, Japan, and
Solamere Technology) via an acoustical optical tunable filter (NEOS). The
confocal head was mounted on an inverted microscope (DM IRE2; Leica,
Germany) equippedwith a 63× glycerol immersion objective (numerical aperture
1.3, HCX PL APO, 21 °C; Leica, Germany) and a motorized Z-stage.Fig. 3. In vivo and in vitro assay of FLII12Pglu series nanosensors. (A) Time depen
perfused with increasing external glucose concentrations. Boxes indicate the loading
Hanks' balanced buffer. HepG2 cells expressing FLII12Pglu series nanosensors wer
25 mM). After each glucose loading (2 min), glucose was withdrawn by perfusion
exposure time) and the cytosolic glucose change was analyzed (FLII12Pglu600µ
FLII12Pglu-δ4 yellow, FLII12Pglu-δ6 blue). (B) In vitro glucose-binding titration cu
single site binding isotherm: S=(r− rapo)/(rsat− rapo)=[gluc]/(Kd+[gluc]), where S is s
absence of glucose; and rsat, ratio at saturation with glucose. (C) In vivo glucose appar
apparent K05, the initial phase was plotted by using the ratio change in 30 s after glFluorescence images (band pass filters of 525/50 nm for yellow fluorescent
protein Citrine-eYFP and 620/60 nm for mCherry) were acquired with a cooled
on-chip multiplication gain Cascade 512B digital camera (Roper Scientific).
Instrumentation was driven using Metamorph version 6.1r5 software (Universal
Imaging Corp.).
2.9. RT-qPCR
Quantitative PCR (qPCR) to measure abundance of expression of GLUTs
and β-actin was performed with cDNA of HepG2 and human liver. Total RNA
was extracted from HepG2 cells using the RNAeasy kit (Qiagen). Human liver
total RNAwas purchased (Clontech). Reverse-transcriptase (RT) reactions were
performed using the Protoscript kit (New England Biolabs) according to the
manufacturer's protocols. Real-time PCR was performed with a DNA Engine
Opticon 2 system (MJ Research, Waltham,Mass.). qPCR involved a preliminary
denaturation (10 min at 94 °C), followed by 40 cycles of amplification and
quantification (10 s at 94 °C, 15 s at 55 to 58 °C, and 15 s at 72 °C, with a single
fluorescence measurement), and an incubation of 10 min at 72 °C, followed by adent ratio change of HepG2 cells expressing the FLII12Pglu series nanosensors
time of external glucose concentrations (mM) during continuous perfusion with
e perfused with gradually increasing concentrations of external glucose (0.1 to
with Hanks' balanced buffer. FRET images were acquired every 10 s (600 ms
magenta, FLII12Pglu-10aa red, FLII12Pglu-15aa green, FLII12D183A cyan,
rves of FLII12Pglu series nanosensors. Labeling as in (A). Data were fitted to a
aturated-binding portion; [gluc], glucose concentration; r, ratio; rapo, ratio in the
ent flux titration curve of FLII12Pglu series nanosensors. To determine the in vivo
ucose loading (Fig. 3A).
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continuous fluorescence measurements) using the DyNAmo HS SYBR green
qPCR kit (New England Biolabs). Primers were designed to be around 150–
300 bp for annealing to exon sequences with the lowest possible degree of
homology to distinguish between the different GLUTs and β-actin.Table 1
Comparison between in vitro Kd and in vivo apparent K0.5
In vitro Kd (µM) In vivo apparent K0.5 (µM)
[in vivo Δ normalized max ratio]
FLII12Pglu-600µ 583±8.0 1060±453
[0.166]
FLII12Pglu-10aa 1480±82 405±150
[0.338]
FLII12Pglu-15aa 2650±260 1540±1910
[0.072]
FLII12Pglu-δ4 600±64 1155
[0.093]
FLII12Pglu-δ6 660±160 601± 44
[0.736]
In vitro glucose Kd was determined as a single site binding isotherm; S=
(r− rapo) / (rsat− rapo)=[gluc] / (Kd+[gluc]), where S is saturated-binding portion;
[gluc], glucose concentration; r, ratio; rapo, ratio in the absence of glucose; and
rsat, ratio at saturation with glucose.
Initial in vivo glucose flux rate detected by FLII12Pglu series nanosensors. To
compare the nanosensor function in vivo, the initial accumulation rate was plotted
by using the ratio change 30 s after glucose loading (Fig. 3A). The in vivo apparent
K0.5 of each nanosensor was determined by r=[gluc] / (K0.5+[gluc]).3. Results
3.1. Development of dynamic FRET glucose sensors for in vivo
analyses
To develop nanosensors better suited tomeasure glucose levels
in the physiological range, the sensitivity and SNRwere improved
by systematic linker-shortening for the high sensitivity intramo-
lecular FRET nanosensor FLII12Pglu-600µ [7]. The constructs
were named FLII12Pglu-1aa through FLII12Pglu-17aa, with Xaa
indicating the number of amino acids that were deleted by site-
directed mutagenesis. Two additional constructs were generated
in which MglB and Citrine-eYFP were kept intact and four or six
amino acids of the synthetic linker were deleted yielding
FLII12Pglu-δ4 and FLII12Pglu-δ6, respectively (Fig. 2A). Sur-
prisingly, contrary to observationsmadewhen deleting sequences
from the original terminally fused FLIPglu sensor [7], most of the
FLII12Pglu deletion nanosensors showed a decreased Δratio
compared to the original FLII12Pglu-600 μ when titrated with
glucose in vitro in 20 mMMOPS buffer. Only FLII12Pglu-δ4 and
FLII12Pglu-δ6 showed ratio changes similar to FLII12Pglu-600 μ
(Fig. 2B top). No correlation was found between linker length and
Δratio, suggesting that linker composition is more relevant than
length, and that the relative position of the fluorophores may be
important for FRET efficiency. Addition of glucose to purified
protein resulted in a decrease in eCFP emission and an increase in
Citrine-eYFP emission, suggesting that the binding of glucose to
MglB results in a conformational change of FLII12Pglu-700µδ6.
Spectra in the absence or in the presence of glucose show an
isosbestic point at 520 nm (data not shown). The Hill coefficient
for glucose is 1.0. The binding constant (Kd) for glucose was
determined to be 660±160µMwith a maximum normalized ratio
change of 0.5 (Fig. 3B and Table 1).
The FRETsensors exploit protein conformation as a proxy for
ligand concentrations; thus it is expected that other factors, which
affect conformation or the fluorophores can affect the response.
To identify the most robust nanosensor in this collection for in
vivo applications, the effect of Hanks' balanced buffer (pH 7.4)
was assessed on the in vitro Δratio of each nanosensor (Fig. 2B
bottom). Most of the deletion constructs showed a 20–70%
decrease in Δratio in Hanks' balanced buffer, while FLII12Pglu-
δ4, FLII12Pglu-δ6, FLII12Pglu-10aa, FLII12Pglu-12aa and
FLII12Pglu-15aa, showed a higher Δratio compared to
FLII12Pglu-600μ. In addition, the effect of an artificial mam-
malian cytosolic solution (135 mM K-gluconate, 4 mM KCl,
12 mM NaHCO3, 0.8 mMMgCl2, 0.2 mM CaCl2; pH 7.2) on the
nanosensor response was tested (Fig. 2C). Interestingly, both
FLII12Pglu-δ4 and FLII12Pglu-δ6 were largely unaffected in
20 mM MOPS buffer (pH 7.0) or Hanks' balanced buffer (pH
7.4), and there was a good correlation of Δratio between Hanks'
balanced buffer and artificial cytosol (Fig. 2B). FLII12Pglu-10aawas unaffected by Hanks' balanced buffer and slightly affected in
mammalian cytosol (10% decrease compared to FLII12Pglu-
600 μ). In contrast, FLII12Pglu-16aa showed a decrease of about
30%compared to FLII12Pglu-600μ in Hanks' balanced buffer and
mammalian cytosol, and in addition reversed the ratio in response
to ions in Hanks' balanced buffer. Of all nanosensors, FLII12Pglu-
15aa was least affected by buffer composition and even showed an
improved Δratio in Hanks' balanced buffer and mammalian
cytosol over that in 20mMMOPS buffer (Fig. 2B). FLII12Pglu-δ6
has a N10 times higher ratio change over the original FLIPglu-
600µ and is comparable to FLII12Pglu-600μ, and showed
apparently the best robustness under all conditions (Fig. 2B).
Therefore, we tested several intramolecular FRET nanosensor in
addition to FLII12Pglu-δ6 in vivo using HepG2 cells.
3.2. Correlation of in vitro glucose-binding affinity, Kd, and in
vivo apparent glucose, K0.5
The five most promising nanosensors from the in vitro analysis
were selected to determine whether the in vivo response was also
improved over the original FLIPglu series, which showed in vivo
ratio changes of 0.1–0.2. To determine the in vivo apparent glucose
K0.5 of FLII
12Pglu-600µ FLII12Pglu-10aa, FLII12Pglu-15aa,
FLII12Pglu-δ6, FLII12Pglu-δ4, HepG2 cells expressing those
FLII12Pglu series nanosensors were perfused with increasing
concentrations of external glucose using a step protocol (Fig. 3A).
The nanosensor response showed a biphasic behaviour. The in vivo
apparent glucose K0.5 was determined from the slope of the first
phase after each glucose-loading step (Fig. 3C, Table 1).
FLII12Pglu-δ6 showed the highest dynamic ratio change in vivo,
which corresponded to the in vitro glucose-binding titration assay
in artificial cytosolic buffer (Fig. 2C). Surprisingly, the in vivo ratio
changes differed significantly for the deletion variants. FLII12Pglu-
D183A, which has a dramatically reduced binding affinity for
glucose due to a D183A mutation, was used as an in vivo control.
The absence of a response in cells expressing FLII12Pglu-D183A
Fig. 4. (A) Localization of the cytosolic FLII12Pglu-700µδ6 in HepG2 cells. Confocal images of the nanosensor FLII12Pglu-700µδ6 by eCFP excitation in the stably
expressing cell line. Bar: 10 µM (83 pixels). (B) Ratio change of HepG2 cell expressing FLII12Pglu-700µδ6 in HepG2 cells perfused with increasing external glucose
concentrations. Black bars indicate the duration and external glucose concentrations (mM) during perfusion with Hanks' balanced buffer (mean±SD, n=5) (C) Fitted
Michaelis–Menten kinetics of glucose flux as measured by FLII12Pglu-700µδ6 in HepG2 cells.
Table 2
Quantitative GLUT transcripts copy per beta-actin in HepG2 and human liver
using RT-PCR
HepG2 Human liver
GLUT1 107 0.836
GLUT2 3.98 54.6
GLUT3,14 8.96 0.395
GLUT4 0.959 1.55
GLUT5 ND. ND.
GLUT6 0.597 0.968
GLUT7 ND. ND.
GLUT8 0.437 2.21
GLUT9 1.75 5.52
GLUT10 1.64 12.9
GLUT11 0.353 0.439
GLUT12 0.058 0.576
GLUT13 0.382 1.01
ND.: Data was not detected.
Each reaction was the average of two different RT reaction samples.
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are glucose specific (Fig. 3B). FLII12Pglu-700µδ6 showed an
apparent K0.5=600 µM in vivo and a Δratio (normalized) of 0.74
which is more than 3 times larger compared to the first generation
glucose nanosensor FLIPglu-600µ [5]. The reliable detection range
for glucose by FLII12Pglu-700µδ6 was improved from 0.074–
6.1 mM to 0.05–9.6 mM as compared to FLIPglu-600µ (Fig. 1).
To determine cytosolic glucose concentration dynamics,
FLII12Pglu-700µδ6 was targeted to express in the cytosol
(Fig. 4A). FLII12Pglu-700µδ6 was expressed in the cytosol
excluding vesicles. HepG2 cells expressing FLII12Pglu-700µδ6
were perfused with gradually increasing concentration of external
glucose (Fig. 4B). It was analyzed that FLII12Pglu-700µδ6
showed saturation over 10 mM. It was shown that Michaelis–
Menten fitting of cytosolic accumulation rate versus extracellular
glucose concentration (K0.5=1.54±0.30mM, andVmaxwas 3.91±
0.22 Δratio/min in Fig. 4C), which is comparable to GLUT1
affinity to D-glucose on plasma membrane [11].
3.3. Quantitative expression analysis of GLUTs in HepG2 and
human liver cells
We previously reported that most of GLUT members are
expressed in HepG2 cells [12]. It is known that GLUT1 is
highly expressed in HepG2 cells [13], while both primary livercell cultures as well as liver cancer cells lose GLUT2 expression
[14]. To compare glucose transporter gene expression levels in
HepG2 and liver cells, the transcripts for GLUT1-13 were
quantified by qPCR (Table 2). In human liver, GLUT2 has the
highest expression level among GLUT members and GLUT8-10
are also expressed (GLUT2»GLUT10NGLUT9NGLUT8),
while GLUT2 expression was reduced and GLUT1 and
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GLUT3NGLUT2NGLUT9NGLUT10).
3.4. Effect of GLUT siRNA on steady-state glucose levels
To screen for the effect of siRNA silencing of GLUT mem-
bers and the G6P-transporter, G6PT, on the cytosolic glucose
concentration, we measured steady-state glucose levels in
HepG2 cells expressing FLII12Pglu-700µδ6 and siRNA
(Fig. 5). Cy3-labeled negative control oligonucleotide was
measured steady-state glucose levels with siRNA to detect
cotransformed cells. 3 different images (eCFPex/eCFPem,
eCFPex/eYFPem, Cy3) were taken, and the cells in which theFig. 5. siRNA inhibition of GLUT-mediated glucose transport (A) Images of the
cytosolic FLII12Pglu-700µδ6 in HepG2 cells. eCFPex/eCFPem, eCFPex/
eYFPem, images of the nanosensor FLII12Pglu700µ-δ6 by eCFP excitation in
the stably expressing cell line, and Cy3-labeled control oligonucleotide. Stably
transfected HepG2 cells expressing FLII12Pglu700µ-δ6 were cotransfected with
siRNA and Cy3-labeled control oligonucleotides to identify transfected cells.
Bar: 100 µM (50 pixels). (B) Effect of siRNA silencing on the FRET response
after addition of 0.5 mM and 20 mM glucose using ImageXpress.
Representative time courses for siRNA treated cells are shown for GLUT1
and GLUT9 siRNAs. (C) Steady-state glucose levels were compared at different
time points (0.5 min, 0 mM; 2 min, 0.5 mM; 3 min, 20 mM). Statistical analysis
using Students t-test (n=4–18, ⁎⁎Pb0.01).
Fig. 6. Localization of GLUT1-eGFP and GLUT9-eGFP fusion protein and
cytosolic localized mCherry in HepG2 cells using spinning disk confocal
microscopy. Bar: 10 µM (83 pixels).Cy3-red was detected were analyzed (Fig. 5A). Glucose level
was increased by the stepwise glucose loading (Fig. 5B). There
was a significant reduction of the cytosolic glucose steady-state
level in the presence of 0.5 mM and 20 mM glucose by GLUT1
and GLUT9 siRNAs (Fig. 5C).
3.5. Subcellular localization of GLUT1-eGFP fusion proteins
To determine the subcellular localization of GLUT1 and
GLUT9 in HepG2 cells, C-terminal, GLUT-eGFP fusions were
used (Fig. 6). GLUT1-eGFP and GLUT9-eGFP were found to
be mainly localized at the plasma membrane of HepG2 cells.
GLUT1-eGFP was also detected in intracellular compartments
N-terminal eGFP fusions did not show significant fluorescence
in HepG2 cells.
4. Discussion
To be able to measure the effect of siRNA inhibition of
GLUT glucose uniporters on glucose flux, a more robust and
sensitive nanosensor was developed by combining the fluor-
ophore-insertion strategy with a systematic linker-deletion
strategy using the intramolecular glucose nanosensor
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FLII12Pglu-700µδ6 provided the highest in vivo ratio change,
expanding the sensitivity as well as the detection range
significantly (Fig. 1). This sensor was used to analyze the
contribution of GLUT uniporters on glucose flux in HepG2
cells by siRNA inhibition. Consistent with the finding that
GLUT1 is the most highly expressed glucose transporter gene,
inhibition of GLUT1 lead to a strong reduction in glucose
accumulation. Among the other GLUTs, only GLUT9 inhibition
showed a partial inhibition of glucose flux. eGFP-fusions
indicated that both transporters localize primarily to the plasma
membrane. These results suggest that the high sensitivity FLIP
sensor is suitable for high throughput screening of siRNA
collections for components involved in glucose signaling.
4.1. Sensor optimization
The original FLIP sensors provide a suitable system for
analyzing analyte levels in cellular compartments in real time
[5,10,15]. Analysis of the expected change in distance between
the fluorophores and the observed ratio change suggested that
factors other than distance contribute to the FRET change [3,7].
Manipulations that reduced the degrees of rotational freedom of
the fluorophores by tighter fusion of the binding proteins with
the fluorophores or restriction of the rotational freedom by
insertion of one fluorophore into surface-exposed loops of the
binding protein had large effects on the observed FRET change
[7]. Here, both strategies were combined using the intramole-
cular glucose nanosensor FLII12Pglu-600µ which is composed
of the mature glucose/galactose-binding protein MglB from E.
coli into which eCFP had been inserted at position 12, and
which is linearly fused via its C-terminus to N-terminus of
Citrine-eYFP using a 6-amino acid linker [7]. Fluorescent pro-
teins comprise terminal regions, i.e. an N-terminal helix and a
C-terminal coil, that are not required for folding or fluorescence
[16]. Similarly, five amino acids may be deleted from the C-
terminal region of MglB without affecting binding [7]. These
“composite linker domains” together add up to 17 amino acids
that may be deleted from FLII12Pglu-600µ. Systematic dele-
tions gave an unexpected result; in contrast to the linearly fused
FLIPglu-600µ in which deletions of few amino acids did not
lead to an effect on the ratio change, already a single amino acid
deletion from FLII12Pglu-600µ showed a significant decrease in
the ratio change. Not the length of the linker, but the compo-
sition of the linker is apparently key to the ratio change. Thus
the deletion analysis here is only a small sample of the possible
variations of the composite linker (2017 combinations). The
finding that both fluorophores, can be present on the same lobe
of the recognition element, as is the case for some of the intra-
molecular FRET sensors [7] as well as for the phosphate and
glutamate FRET sensors [17,18], together with the finding that
most unmodified sensors show a similar ratio although the dis-
tance change between the fluorophores, as estimated from
crystal structures, is most compatible with a role of the dipole
orientation for the signal.
To identify the nanosensor that is best suited for in vivo
measurements, the series of FLIP deletion mutants was ana-lyzed both in a variety of buffers as well as in vivo. The sensors
showed widely different responses to various buffers and in
vivo, suggesting that alterations in the surface properties of the
binding protein or the fluorophores affect the ratio change.
While these data do not provide new insights that may help
devising a rational way to design FRET sensors, the empirical
approach lead to the identification of FLII12Pglu-δ6, a highly
robust sensor with a large in vivo ratio change, which is not only
much more sensitive than the previous nanosensor FLIPglu-
600µ but also covers a much wider dynamic range.
4.2. Contribution of GLUTs to glucose flux
FRET metabolite sensors can be used to measure in vivo flux
within a cellular compartment in real time. Factors that affect flux,
i.e. uptake, release, synthesis, degradation and compartmentation
of the analyte will be detectable as a change in either the rate of
accumulation, the rate of elimination as well as the cytosolic
steady-state level at a given external supply. HepG2 cells are
derived from liver cells, and have been used asmodels for liver cell
behavior. The cytosolic nanosensor FLII12Pglu-700µδ6 showed
an in vivo saturation at above 10 mM external glucose supply.
The cytosolic glucose accumulation rate showed Michaelis–
Menten kinetics with a half-maximal saturation K0.5=1.5 mM of
extracellular glucose. This value corresponds well with the
affinity of GLUT1 [11], the GLUT member most highly ex-
pressed in HepG2 cells at the RNA level (Table 2). Quantification
of GLUT transcripts in HepG2 cells and human liver using RT-
qPCR (Table 2) showed that GLUT1 and GLUT3 expression was
induced in HepG2 cells, consistent with the observed upregula-
tion of GLUT1 in malignant cells and associated with hypoxia-
induced upregulation of GLUT1 and/or GLUT3 [19–21].
GLUT2 expression was reduced compared to normal liver, but
was still higher than most other GLUT members (except
GLUT1). GLUT9 is expressed exclusively in gluconeogenic
tissues such as kidney and liver, while expression is low in the
small intestine [22], and a GLUT9-splice variant is upregulated in
diabetes [23]. Interestingly, its pancreatic expression is regulated
by glucose [24]. The physiological function of GLUT9 as well as
its transport properties are unknown.
RNA levels do not necessarily reflect the activity of an
enzyme. We therefore analyzed the contribution of individual
GLUTs to glucose flux using a set of siRNAs to inhibit glucose
uptake. Among the twelve GLUT siRNAs tested for effects on
glucose flux with the help of FLII12Pglu-700µδ6 using a high
throughput-imaging platform, only GLUT1 and GLUT9 had a
significant effect on glucose-induced FRET changes. Consistent
with the high overexpression of GLUT1, GLUT1 siRNAs had a
strong inhibitory effect on glucose-induced FRET increases.
Interestingly, GLUT9 showed a partial effect on glucose flux.
Consistent with the effect of siRNA inhibition, both GLUT1-
and GLUT9-eGFP fusions were found to localize mainly to the
plasma membrane. These results demonstrate that GLUT9, al-
though only lowly expressed, can contribute to glucose flux.
Moreover, the results are a proof-of-concept that siRNA screens
can be performed using the new generation of FRET sensors to
identify proteins that affect sugar flux.
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Hepatic glucose concentration measurements are important in
the context of pathological conditions such as diabetes. The im-
proved sensitivity and dynamic range of the glucose nanosensor
FLII12Pglu-700µδ6 provides a reliable means for analyzing
glucose level analysis in vivo, e.g. in cell cultures, but probably
also in intact organisms such as Caenorhabditis elegans, Droso-
phila, or zebra fish. The next step will be to test the effect of
kinases and phosphatases, e.g. the serum and glucocorticoid-
inducible SGK, which has been suggested to affect GLUT1
activity, on the overall sugar flux [25]. The new generation of
FRETsensors is expected to help unravel openquestions regarding
sugar homeostasis and its regulation and provide a new means for
the development of drugs using high-content screens.
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